Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 127-134

  Sakurama, Kazufumi ^a   Noma, Kazuhiro ^a   Takaoka, Munenori ^a   Tomono, Yasuko ^b   Watanabe, Nobuyuki ^a   Hatakeyama, Shinji ^d   Ohmori, Osamu ^d   Hirota, Seiichi ^e   Motoki, Takayuki ^a   Shirakawa, Yasuhiro ^a   Yamatsuji, Tomoki ^a   Haisa, Minoru ^c   Matsuoka, Junji ^a   Tanaka, Noriaki ^a   Naomoto, Yoshio ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Shigei Medical Research Institute   (Japan)

^c Okayama Citizens Hospital   (Japan)

^d NOVARTIS PHARMA K K   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; IMATINIB; PROTEIN KINASE B; STEM CELL FACTOR; TAE 226; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GASTROINTESTINAL STROMAL TUMORS; MICE; MICE, NUDE; MORPHOLINES; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SUBSTRATE SPECIFICITY;

EID: 58149484784     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0884     Document Type: Article

References (46)

1. Joensuu H. Gastrointestinal stromal tumor (GIST) [review]. Ann Oncol 2006;17 Suppl 10:x280-6.
2. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;23:3999-4006.
3. Koon N, Schneider SR, Sarlomo RM, et al. Molecular targets for tumor progression in gastrointestinal stromal tumors. Gut 2004;53:235-40.
4. Matkowskyj KA, Keller K, Glover S, Kornberg L, Tran-Son-Tay R, Benya RV. Expression of GRP and its receptor in well-differentiated colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407. J Histochem Cytochem 2003;51:1041-8.
5. Schlaepfer DD, Hunter T. Signal transduction from the extracellular matrix - a role for the focal adhesion protein-tyrosine kinase FAK. Cell Struct Funct 1996;21:445-50.
6. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999;71:435-78.
7. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000;2:249-57.
8. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000;19:5606-13.
9. Schwartz MA, Ginsberg MH. Networks and crosstalk: integrin signaling spreads. Nat Cell Biol 2002;4:E65-8.
10. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A 1992;89:5192-96.
11. Hanks SK, Calalb MB, Harper MC, Patel SK. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A 1992;89:8487-91.
12. Schaller MD. The focal adhesion kinase. J Endocrinol 1996;150:1-7.
13. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003;116:1409-16.
14. Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T. Anti apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 2000;275:16309-15.
15. Gabarra-Niecko V, Schaller MD, Unty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003;22:359-74.
16. Owens LV, Xu L, Craven RJ, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 1995;55:2752-5.
17. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005;5:505-15.
18. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004;14:92-101.
19. Kornberg LJ. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck 1998;20:745-52.
20. Cance WG, Harris JE, Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000;6:2417-23.
21. Kim SJ, Park JW, Yoon JS, et al. Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study. J Korean Med Sci 2004;19:710-5.
22. Sood AK, Coffin JE, Schneider GB, et al. Biological significance of focal adhesion kinase in ovarian cancer. Am J Pathol 2004;165:1087-95.
23. Kornberg LJ. Focal adhesion kinase expression in oral cancers. Head Neck 1998;20:634-9.
24. Lark AL, Livasy CA, Calvo B, et al. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res 2003;9:215-22.
25. Theocharis SE, Kouraklis GP, Kakisis JD, et al. Focal adhesion kinase expression is not a prognostic predictor in colon adenocarcinoma patients. Eur J Surg Oncol 2003;29:571-4.
26. Itoh S, Maeda T, Shimada M, et al. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res 2004;10:2812-7.
27. Furuyama K, Doi R, Mori T, et al. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg 2006;30:219-26.
28. Carelli S, Zadra G, Vaira V, et al. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer 2006;53:263-71.
29. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Ann Oncol 2005;16:566-78.
30. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;29:4764-74.
31. Koyama T, Nimura H, Kobayashi K, et al. Recurrent gastrointestinal stromal tumor of the stomach associated with a novel c-kit mutation after imatinib treatment. Gastric Cancer 2006;9:235-9.
32. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-49.
33. Debiec RM, Dumez H, Judson I, et al. Use of c-KIT/ PDGFA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
34. Debiec RM, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270-9.
35. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
36. Isozaki K, Bonoit T, Jacques B, et al. Germline-activating mutations in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000;157:1581-5.
37. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-5.
38. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutations of KIT gene. Gastroenterology 2002;122:1493-9.
39. Chen H, Isozaki K, Kinoshita K, et al. Imatinib inhibits various types of activating mutant c-kit found in gastrointestinal stromal tumors. Int J Cancer 2003;105:130-5.
40. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007;13:4874-81.
41. Halder J, Lin YG, Merritt WM, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007;67:10976-83.
42. Liu TJ, LaFortune T, Honda T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007;6:1357-67.
43. Shi Q, Hjelmeland AB, Keir ST, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007;46:488-96.
44. Golubovskaya VM, Virnig C, Cance WG. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 2008;47:222-34.
45. Watanabe N, Takaoka M, Sakurama K, et al. Dual-tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res 2008;14:4631-9.
46. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.